NutriStack
Potassium and Ranolazine, a synergy.
Ranolazine usually causes modest QT prolongation, but torsades de pointes has been reported when risk factors stack. Low potassium is a major modifiable risk factor for drug-induced torsades. Potassium supplementation is only appropriate when potassium is low or intake is inadequate and should be monitored.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Potassium and Ranolazine
- Pair type
- Synergy
- Evidence (highest tier)
- Moderate
- Source citations
- 3 sources
- Stack Score effect
- +2 to your Stack Score (per scored synergy row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Synergy · Moderate evidence
Synergy
What is happening. Ranolazine usually causes modest QT prolongation, but torsades de pointes has been reported when risk factors stack. Low potassium is a major modifiable risk factor for drug-induced torsades. Potassium supplementation is only appropriate when potassium is low or intake is inadequate and should be monitored.
Mechanism. Ranolazine inhibits late sodium current and can inhibit IKr, causing QT prolongation. Hypokalemia lowers repolarization reserve and increases the chance that QT prolongation progresses to torsades.
Recommendation. Keep potassium in the normal range while using ranolazine, especially if you take diuretics or have vomiting or diarrhea. Do not start potassium supplements without clinician monitoring, and report fainting, near-fainting, or new sustained palpitations promptly.
Sources (3)
- Liu Z, Williams RB, Rosen BD. The potential contribution of ranolazine to Torsade de Pointe. J Cardiovasc Dis Res. 2013;4(3):187-190. PMID 24396259
- Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol. 2004;142(8):1300-1308. PMID 15277312
- Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139-152. PMID 27212965
Stack Score
How this pair moves the number.
Effect on the composite score
If both Potassium and Ranolazine are in the same stack, this pair applies +2 to your Stack Score (per scored synergy row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.